Olesinski E, Bhatt S. Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models. STAR Protoc. 2021;2:100461pubmedpublisher Riether C, Radpour R, Kallen N, Bürgin D, Bachmann C, Schürch C,et al. Metoclopramide treatment blocks...
However, the antagonistic effects of the combination therapy have been observed in PD-L1 CAR-T cells when applied in addition to the mesothelin-targeting CAR-T cells [49]. In such a case, the activated mesothelin-targeting CAR-T cells probably expressed PD-L1 and were targeted by PD-L1 ...
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic ReviewHEMATOPOIETIC stem cellsSTEM cell transplantationMULTIPLE myelomaCD34 antigenDARATUMUMAB...
βAS3- or γ-globin vectors may be applied to clinical gene therapy of sickle cell disease Sickle cell disease (SCD) can be cured by allogeneic hematopoietic stem cell transplant. However, this is only possible when a matched donor is available, making the development of gene therapy using au...
Objective To explore the effect of antilymphocyte globulin (ALG) as a main regimen of immunosuppressive therapy on sever aplastic anemia (SAA-Ⅰ) and very sever aplastic anemia (vSAA) in children. Methods One hundred and thirty-seven children with severe aplastic anemia were treated with ALG from...
Combination of GM-CSF with oncolytic therapy may be particularly effective as the necrotic cell death accompanying virus replication should serve to effectively release tumour antigens to then induce a GM-CSF-enhanced immune response. This would, in effect, provide an in situ, patient-specific, ...
Raheleh FarahzadiEzzatollah FathiSomayeh VandghanooniBehnaz ValipourRegenerative Therapy
was defined as a multicomponent QRS signal and the cut-off value for normal QRS fragmentation was ≤ 4 positive peak deflections.Results: Of 20 patients included, 6 (30%, Group A) did not experience VA and 14 (70%, Group B) continued to have VA in 12 months after cell therapy. The...
Gene therapy is a promising treatment of SCD, and two different gene therapy drugs, using gene editing or gene transfer, have already reached the marketing stage. There is still a need to improve the efficacy of gene therapy in SCD, particularly when using anti-sickling beta-globin gene ...
The first phase 2 gene therapy trial for HIV-1 has shown some promising signs. There's a long way to go before this would be a viable approach in people with HIV—this trial did not show a statistically significant difference in viral load at the primary end point–but other analyses ...